OVERVIEW

Adopting the New Therapeutic “Lineup” to Manage ASCVD - East is organized by Medtelligence.

Released: 02/28/2022
Valid until: 02/28/2023

Overview:
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
• Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
• Identify barriers to the implementation of effective, long-term management of ASCVD